GlassScriptPhysician profile
Carlos Rosas
NPI 1265773907
$2,377.01
in general payments reported to CMS, 2019-2025
22 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $661 · 2023: $709 · 2024: $283 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.12 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $177.52 | 2022-2024 | |
| Lilly USA, LLC | $156.87 | 2021-2024 | Mounjaro, Trulicity |
| Abbvie INC. | $154.25 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $142.36 | 2021-2024 | Verquvo, Steglatro |
| Astellas Pharma US INC | $121.59 | 2022-2024 | Veozah |
| Amgen INC. | $115.12 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $64.37 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Insulet Corporation | $57.92 | 2023-2025 | Omnipod |
| Stryker Corporation | $53.19 | 2021 | |
| Amarin Pharma, INC. | $49.83 | 2021 | |
| Pfizer INC. | $41.22 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $32.64 | 2023-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $25.23 | 2022 | |
| Abbott Laboratories | $22.17 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.55 | 2023 | Farxiga |
| Corcept Therapeutics | $19.53 | 2024 | Korlym |
| Mannkind Corporation | $18.85 | 2022 | |
| Exact Sciences Corporation | $17.48 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $17.20 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $14.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.